In total, 96 NSCLC patients treated in 2nd line using the ISET platform to isolate CTCs were studied by Guibert et al. They found a higher PD-L1 positivity rate for CTCs than for tissues (83% vs. 41%). The gene discussed is CD274; the disease is non-small cell lung carcinoma.